Kumho HT, Dinona's 'dNP007 Antibody Treatment' Clinical Plan Approved for Merger

On the 9th, it was announced through a press release that the 'DNP007 antibody treatment' under development by Dynona, which is pursuing a merger with Kumho HT, had been approved by the Ministry of Food and Drug Safety on the 9th.

DNP007 is known as an antibody that induces acquired immune tolerance represented by T cells by regulating dendritic cells. Immune tolerance is an important mechanism of protection from autoimmune cells to prevent immune cells from attacking themselves. If immune tolerance is not achieved, serious autoimmune diseases such as rheumatoid arthritis and multiple sclerosis can occur.

A company official said, "Through the unique mechanism of the DNP007 antibody that regulates dendritic cells, it is expected that an effective treatment for autoimmune diseases with fewer side effects will be developed."

He continued, “DNP007 has a mechanism for resolving organ transplant rejection, so it is expected that it can replace immunosuppressants with severe side effects from steroids. ” he added.

The DNP007 antibody therapy is scheduled to undergo a phase 1 trial at Seoul National University Hospital to confirm 'safety, tolerability, and pharmacokinetic properties' in normal subjects.

Meanwhile, Dinona is currently pursuing a merger with Kumho HT, the second largest shareholder, with a 16.30% stake. The largest shareholder of Dinona is S-Mac, which holds a 25.81% stake.